Elotuzumab Accepted for Priority Review by FDA for Previously-Treated Patients With Multiple Myeloma
The submission by BMS includes results from the ELOQUENT-2 trial that were recently published in the New England Journal of Medicine. The FDA has accepted elotuzumab, being developed as Empliciti, for ...
Please provide your email address to receive an email when new articles are posted on . The addition of elotuzumab to bortezomib and dexamethasone induced clinical benefit without added toxicity in ...
In March 2014, Dana Farber Cancer Institute’s Kenneth C. Anderson, MD, raised expectations at the annual gathering of the National Comprehensive Cancer Network when he said it wouldn’t be long before ...
Please provide your email address to receive an email when new articles are posted on . The addition of the elotuzumab to pomalidomide and dexamethasone conferred a significant PFS benefit among ...
Elotuzumab (Empliciti) failed for a third time to improve progression-free survival (PFS) in newly diagnosed multiple myeloma when added to standard therapy, a large randomized trial showed. After 4 ...
Review the side-effects of Elotuzumab as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...
Dublin, Feb. 16, 2023 (GLOBE NEWSWIRE) -- The "Elotuzumab Emerging Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering. This report provides ...
• Elotuzumab comes in a powder form which should be mixed with sterile water. It should be given intravenously or directly into the vein by a health care provider in a hospital setting. • Two doses of ...
Exploring the Relationship Between Patient Age and Cancer-Specific Survival in Papillary Thyroid Cancer: Rethinking Current Staging Systems Treatment options and outcomes for patients with multiple ...
More treatment options for multiple myeloma have generated more complex clinical decisions, and new Predictors of worse progression-free survival included ISS stage II, ISS stage III, and adverse ...
Addition of the immunostimulatory antibody elotuzumab to the combination of lenalidomide and dexamethasone improves progression-free survival (PFS) and the overall response rate (ORR) in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results